Search Results for “AI” – Page 7 – media

Donated 160 million yuan to the Qinghai-Tibet Plateau

Under the guidance of the Central United Front Work Department, the Beijing Tongxin Gongzhu Public Welfare Foundation’s “Together, Forge a Chinese Heart” fund launched the 2024 “Together, Forge, Warm the Plateau” series of donation activities on the 5th, sending medical supplies worth 163 million yuan to the people in the Qinghai-Tibet Plateau. In early July, the Beijing Tongxin Gongzhu Public Welfare Foundation invited more than 800 medical experts from the capital, including Dong Jiahong, an academician of the Chinese Academy of Engineering, and Wang Jianliu, secretary of the Party Committee of Peking University People’s Hospital, to Ganzi Tibetan Autonomous Prefecture, Sichuan Province to carry out the “Together, Forge a Chinese Heart” medical charity event. The event lasted for one week, and 90 free clinics were set up in 18 counties (cities) in Ganzi Prefecture, with 73,000 free clinics, 10.8 million yuan worth of medicines distributed, and 52 operations such ...
- Source: https://mp.weixin.qq.com/
- 82
- September 11, 2024
635 million US dollars! Anmai Biological BCMA × CD3 Double Antibody Successfully Goes to Sea

Anmai Biotechnology announced that it has reached a licensing agreement with Vignette Bio for the T cell conjugation (TCE) molecule EMB-06 targeting BCMA. According to the agreement, Amway Bio will grant Vignette the exclusive right to develop and commercialize EMB-06 outside the Greater China region (including Chinese Mainland, Hong Kong, Macao and Taiwan), and Amway Bio will reserve the right of EMB-06 in the Greater China region. Anmai Biotechnology will receive a total down payment of $60 million in cash and Vignette equity, and will have the right to receive up to $575 million in milestone payments for development, listing, and commercialization, as well as revenue sharing based on net sales. EMB-06 is the first TCE molecule developed under the T cell conjugation platform of Anmai Biotechnology, which combines Anmai Biotechnology’s self-developed FIT Ig bispecific antibody platform and CD3 binding domain library, as well as Anmai Biotechnology’s internal new drug ...
- Source: drugdu
- 67
- September 11, 2024
Vaxcyte’s stock price soared after achieving a ‘stunning’ victory in the competition against Pfizer’s 31 valent pneumococcal conjugate vaccine (PCV)

Editor’s Bio Products Circle Vaxcyte has released Phase 1/2 data for its 31 valent pneumococcal vaccine candidate, which analysts have described as “astonishing”. If these data can be replicated in large-scale critical studies, it could pose a serious threat to Pfizer’s Prevnar 20. Vaxcyte’s half period data for VAX-31 in adults aged 50 and above against Prevnar 20 is “extraordinary” and suggests a “killer product in the pneumococcal conjugate vaccine category,” said analysts at Leerink Partners in a report on Tuesday. Leerink analyst said, “We believe that these data support VAX-31’s potential to gain a significant market share in the pneumococcal conjugate vaccine market expected to exceed $10 billion by 2030+ Due to this positive reading, Mizuho analysts referred to it as the “best case scenario,” and Vaxcyte’s stock price jumped about 44% at the release time on Tuesday morning.Today, we are opening a new chapter for Vaxcyte as we ...
- Source: drugdu
- 81
- September 9, 2024
Spending 1.3 billion, Sinopharm Group strikes again

Recently, Tiantan Biological announced that its holding subsidiary Chengdu Rongsheng Pharmaceutical Co., Ltd. intends to acquire 100% equity of Wuhan Zhongyuan Ruide Biological Products Co., Ltd., a wholly-owned subsidiary of CSL BEHRING ASIA PACIFIC LIMITED (Jetbehring (Asia Pacific) Co., Ltd.) for a total amount of US$185 million (nearly RMB 1.33 billion). Among them, the equity acquisition price is US$138 million, and the remaining amount is provided by Chengdu Rongsheng to Zhongyuan Ruide to repay the shareholder loan of CSL Asia Pacific to Zhongyuan Ruide (hereinafter referred to as “CSL”, “Zhongyuan Ruide” and “this acquisition”). After the completion of this transaction, Zhongyuan Ruide will become a holding subsidiary of Tiantan Biological, and its financial statements will be consolidated. For Tiantan Biological, this is a deal that adds icing on the cake. Blood products are a rigid demand track with extremely high barriers, and “whoever gets the plasma station will win the ...
- Source: drugdu
- 74
- September 9, 2024
Secondary bargaining “liberalized”

Secondary bargaining will become an important tool for price governance. In a broad sense, secondary bargaining refers to the second price negotiation between the buyer and the seller during the transaction process, outside the established bargaining results. Specifically at the drug procurement level, it is the act of the purchasing units below the provincial level (such as cities, medical communities/medical alliances, hospitals, etc.) initiating bargaining with suppliers again outside the mainstream provincial drug prices. Although secondary bargaining has always been controversial, the behavior of hospitals in secondary bargaining is very common in the industry. The reasons are as follows: First, there is no prohibition in major policies. At the national level, it is only clear that secondary bargaining is not allowed for drugs selected in centralized procurement. For ordinary drugs listed on the Internet, price governance itself is a process in which multiple parties participate in the formation of a ...
- Source: drugdu
- 70
- September 9, 2024
Hainan Free Trade Harbor Drugs, Medical Equipment to Enjoy “zero Tariffs”

People’s Daily, Beijing, September 6 (Reporter Wang Zhen) According to the General Administration of Taxation website, September 5, the Ministry of Finance, the National Health Commission, the General Administration of Customs, the General Administration of Taxation, the State Administration of Pharmaceutical Administration and other five departments issued a notice on the Hainan Free Trade Port drugs, medical equipment “zero tariff” policy. The notice makes it clear that before the closure of the entire island operation, in Boao Lesheng International Medical Tourism Pioneer Zone in Hainan, registered with an independent legal personality and recognized medical institutions, medical education institutions of higher learning, pharmaceutical research institutes, the import of medicines and medical devices under the provisions of this notice, and in accordance with the provisions of the use of import tariffs can be exempted from import tariffs, import link value-added tax. The introduction of “zero tariff” policy for drugs and medical devices ...
- Source: drugdu
- 72
- September 7, 2024
635 million US dollars! Anmai Biological BCMA × CD3 Double Antibody Successfully Goes to Sea

On September 4th, Anmai Biotechnology announced that it has reached a licensing agreement with Vignette Bio for the T cell conjugation (TCE) molecule EMB-06 targeting BCMA. picture According to the agreement, Amway Bio will grant Vignette the exclusive right to develop and commercialize EMB-06 outside the Greater China region (including Chinese Mainland, Hong Kong, Macao and Taiwan), and Amway Bio will reserve the right of EMB-06 in the Greater China region. Anmai Biotechnology will receive a total down payment of $60 million in cash and Vignette equity, and will have the right to receive up to $575 million in milestone payments for development, listing, and commercialization, as well as revenue sharing based on net sales. EMB-06 is the first TCE molecule developed under the T cell conjugation platform of Anmai Biotechnology, which combines Anmai Biotechnology’s self-developed FIT Ig bispecific antibody platform and CD3 binding domain library, as well as Anmai ...
- Source: drugdu
- 62
- September 6, 2024
The Lancet reports that semaglutide has the potential to be used in heart failure patients

Recently, The Lancet published a new centralized, participant level analysis of heart failure patients with mild reduced ejection fraction or preserved ejection fraction (HFpEF) from four randomized placebo-controlled trials (2.4 mg for SELECT, STEP-HFpEF, STEP-HFpEF DM; 1.0 mg/d). picture According to analysis, semaglutide reduced the composite risk of cardiovascular (CV) death or worsening heart failure (HF) events by 31%, with incidence rates of 5.4% in the semaglutide group and 7.5% in the placebo group (HR 0.69; 95% CI 0.53-0.89; P=0.0045). semaglutide also reduced the risk of HF worsening by 41% (2.8% vs. placebo 4.7%; HR 0.59 (95% CI 0.41-0.82), p=0.0019). Simeglutide had no significant effect on the incidence of CV mortality (3.1% in the Simeglutide group and 3.7% in the placebo group). Hr 0.82 (95% CI 0.57-1.16), p=0.25) The statistical analysis did not adjust for multiplicity, and the hazard ratio should not be used to infer definitive treatment efficacy. In ...
- Source: drugdu
- 72
- September 5, 2024
semaglutide is gaining ground

As we enter 2024, the global competition for “King of Medicine” is becoming increasingly fierce. In the first half of the year, Merck’s PD-1 monoclonal antibody pembrolizumab (trade name: Keytruda, “Keytruda”) successfully won the title of the world’s “king of medicine” with $14 billion. Novo Nordisk’s semaglutide (including 3 brands: Ozempic/Rybelsus/Wegovy) ranked second with sales of about $13 billion in the first half of this year, further narrowing the gap with Keytruda, and the year-on-year growth rate exceeded 40%, leaving suspense for the “king of medicine” competition in the second half of the year. On the other hand, in terms of sales growth, Eli Lilly’s tirpotide (including two brands: Mounjaro/Zepbound) grew 330% year-on-year in the first half of this year to $6.658 billion, making it the fastest-growing drug in history. Since its first indication was approved in 2022, it has grown into a super blockbuster with annual sales of over ...
- Source: drugdu
- 64
- September 5, 2024
Why are small hearing aids stuck in the neck?

Although hearing aids do not look complicated, their research and development is not simple at all. Digital hearing aids use nonlinear amplification to compress and limit loud sounds and amplify small sounds, making the processed sounds comfortable and clear. To achieve this process, digital hearing aids use DSP digital signal processing chips, use digital technology to segment sound signals, and integrate adaptive noise reduction, acoustic feedback suppression, equalizers and other algorithms that can improve the performance of hearing aids, making the sound of hearing aids clearer and more capable of suppressing whistling. Therefore, in the transformation process of digital hearing aids, the core technology threshold is indeed mainly concentrated in two key areas: First, digital hearing aid chips. These chips are the heart of hearing aids, responsible for processing sound signal amplification, filtering, digital processing, etc. They need to have the characteristics of high speed, low power consumption and high ...
- Source: drugdu
- 67
- September 5, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.